



HEPATITIS C TREATMENT PROTOCOL
April, 2002



* Either peginterferon alpha-2b with Rebetol, Rebetrone, or peginterferon alpha-2a with Ribavirin (when available)

** See dosing guidelines (per drug manufacturer)

*** With Rebetrone, discontinue after 24 wks. in absence of Stage 3 or 4 disease by biopsy or clinical evidence of cirrhosis. FDA approval for Peg-Intron A + Ribavirin was for treatment course of 48 wks. across all genotypes. Option to evaluate prognostic factors to determine length of treatment is based on prior experience with Rebetol.



*Peg-Intron results in 25% SVR in naïve patients compared to 12% with Intron-A. Therefore, Intron-A would be recommended only in special circumstances (e.g., low platelets, severe injection site reaction or other allergy to pegylated interferon).